Ulcerative Colitis Management

Introduction to Treatment

The American Gastroenterological Association recommends standard-dose oral mesalamine (2-3 g/day) as first-line therapy for patients with ulcerative colitis, with higher doses (>3 g/day) indicated for suboptimal response or moderate disease activity 1
Standard dose oral mesalamine is defined as 2-3 g/day, with once-daily dosing preferred over multiple daily doses for similar efficacy and better adherence 1, 2

Oral mesalamine (standard-dose 2-3 g/day) is recommended as a first-line therapy for ulcerative colitis, with high-dose mesalamine (>3 g/day) being superior to low-dose (<2 g/day) for induction of remission (RR 0.81, 95% CI 0.71-0.92) 1, 3
Standard-dose mesalamine (2-3 g/day) is superior to low-dose for induction (RR 0.88, 95% CI 0.79-0.99) and maintenance of remission (RR 0.63, 95% CI 0.55-0.78) 3
The recommended dosing for initial treatment is 2.4 g daily for patients weighing 24-35 kg, 3.6 g daily for patients weighing >35-50 kg, and 4.8 g daily for patients weighing >50 kg 1

Adding rectal mesalamine to oral therapy is recommended for better efficacy 1
For suboptimal response, increasing to high-dose mesalamine (>3 g/day) plus rectal mesalamine is recommended 1
For patients with inadequate response to standard-dose, increasing to high-dose mesalamine (>3 g/day) is recommended 3

Mesalamine enemas are preferred over oral therapy alone for left-sided UC/Proctosigmoiditis 1
Sulfasalazine (2-4 g/day) may be considered for patients with prominent arthritic symptoms if mesalamine is cost-prohibitive 1
Alternative therapies for extensive mild-moderate UC include diazo-bonded 5-ASA (balsalazide, olsalazine), as suggested by the American Gastroenterological Association 1
Rectal corticosteroid therapy is recommended as the next best treatment option for induction of remission in patients with ulcerative proctitis who cannot tolerate mesalamine, with low-quality evidence, as suggested by the American Gastroenterological Association (AGA) 1

Periodic monitoring (every 3-6 months) of renal function is essential for patients with ulcerative colitis on mesalamine therapy, with more frequent monitoring for patients with pre-existing renal disease 4
Evaluate renal function prior to initiation and periodically during therapy 1
Fecal calprotectin is recommended to be monitored every 6-12 months in patients in symptomatic remission, and is particularly useful in patients where biomarkers have historically correlated with endoscopic disease activity 4
Elevated levels of fecal calprotectin (>150 mg/g) indicate a 4.4 times higher risk of disease relapse 4
Periodic monitoring of liver function is based on clinical symptoms, as abnormal liver function is a reported adverse effect of mesalamine, although the exact monitoring frequency is not specified 4
Consider periodic liver function tests 1

Interstitial nephritis is a rare but potential adverse effect of mesalamine 1
Abnormal liver function tests are a common adverse reaction in adults (≥2%) 1
The most common adverse reactions in adults (≥2%) include headache, flatulence, abnormal liver function tests, abdominal pain, and diarrhea 1
Patients on mesalamine therapy should be monitored for signs of mesalamine-induced acute intolerance syndrome, which may mimic ulcerative colitis flare, as well as signs of hypersensitivity reactions including myocarditis and pericarditis 4, 1

For extensive UC, oral mesalamine with addition of rectal mesalamine is recommended, while for left-sided UC/Proctosigmoiditis, mesalamine enemas are preferred over oral therapy alone, as recommended by the American Gastroenterological Association 1
For left-sided UC/Proctosigmoiditis, oral mesalamine may be considered as an alternative if the patient values convenience over efficacy, as suggested by the American Gastroenterological Association 1
For ulcerative proctitis, mesalamine suppositories are preferred, while rectal corticosteroid therapy is recommended for intolerance or refractoriness, according to the American Gastroenterological Association 1
If refractory to optimized 5-ASA therapy, adding oral prednisone or budesonide MMX is recommended, according to the American Gastroenterological Association 1